46333XAF5
Ironwood Pharmaceuticals, Inc.
Could not find a ticker for this position, may be a filing error
A Boston-based biotechnology company that develops and sells medicines for digestive and rare diseases, best known for Linzess, a prescription treatment for chronic constipation and irritable bowel syndrome. It began in 1998 as Microbia, founded by postdocs from a Whitehead Institute lab, and renamed itself Ironwood in 2008 after the long-lived desert tree that shelters other plants — a nod to endurance. Its flagship drug linaclotide was discovered by those same early researchers.
CONVERTIBLEUnderlying: IRWDCUSIP: 46333XAF5HealthcareUS1 derivative reporter
0.75% Convertible Senior Notes due 2024
No tracked superinvestor held this security as stock in this period — only the derivative positions below reference it.
Derivative Reporters
Investor
Kind
13F reported value
Quantity
Change
